Acumen Pharmaceuticals Inc
ABOS
Company Profile
Business description
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
Contact
1210-1220 Washington Street
Suite 210
NewtonMA02465
USAT: +1 617 344-4190
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
52
Stocks News & Analysis
stocks
Undervalued by 17%, this US cybersecurity leader is a buy for 2026
Here’s a wide-moat company with strong secular tailwinds in a promising industry—and an attractive stock price, too.
stocks
Tough conditions for ASX listed wagering leader
Wagering continues to be challenged in Australia.
stocks
Chart of the Week: Inflation fears dampen sentiment on retailers
Rising inflation is the fly in the ointment.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,060.60 | 13.10 | -0.14% |
| CAC 40 | 8,243.47 | 9.55 | 0.12% |
| DAX 40 | 25,127.46 | 5.20 | 0.02% |
| Dow JONES (US) | 49,266.11 | 270.03 | 0.55% |
| FTSE 100 | 10,044.69 | 3.52 | -0.04% |
| HKSE | 26,213.68 | 64.37 | 0.25% |
| NASDAQ | 23,480.02 | 104.26 | -0.44% |
| Nikkei 225 | 51,692.70 | 575.44 | 1.13% |
| NZX 50 Index | 13,711.71 | 5.15 | -0.04% |
| S&P 500 | 6,921.46 | 0.53 | 0.01% |
| S&P/ASX 200 | 8,732.20 | 14.70 | -0.17% |
| SSE Composite Index | 4,114.60 | 31.62 | 0.77% |